TD Cowen Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price decreased by research analysts at TD Cowen from $86.00 to $75.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s target price points to a potential upside of 142.33% from the stock’s current price.

A number of other equities analysts have also recently commented on RARE. Canaccord Genuity Group cut their target price on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Wedbush dropped their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research note on Monday, July 14th. Wells Fargo & Company assumed coverage on shares of Ultragenyx Pharmaceutical in a research note on Monday, October 20th. They set an “overweight” rating and a $65.00 target price for the company. Truist Financial lowered their price target on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Morgan Stanley reduced their price objective on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, July 14th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $82.75.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock opened at $30.95 on Wednesday. The stock’s 50-day moving average is $31.45 and its two-hundred day moving average is $32.89. Ultragenyx Pharmaceutical has a 1 year low of $25.81 and a 1 year high of $53.04. The firm has a market cap of $2.98 billion, a price-to-earnings ratio of -5.60 and a beta of 0.30.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). The firm had revenue of $159.93 million during the quarter, compared to analyst estimates of $167.42 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm’s revenue for the quarter was up 14.6% compared to the same quarter last year. During the same period last year, the company earned ($1.40) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, research analysts predict that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,942 shares of the business’s stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $31.51, for a total transaction of $250,252.42. Following the transaction, the chief financial officer owned 98,227 shares in the company, valued at approximately $3,095,132.77. The trade was a 7.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $31.17, for a total value of $76,366.50. Following the completion of the sale, the executive vice president directly owned 73,271 shares of the company’s stock, valued at $2,283,857.07. This represents a 3.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 10,456 shares of company stock worth $328,486 in the last ninety days. 5.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 323 shares during the period. Parallel Advisors LLC lifted its position in shares of Ultragenyx Pharmaceutical by 1,061.9% during the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 669 shares during the period. Assetmark Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 205.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,169 shares during the period. Finally, Covestor Ltd grew its holdings in shares of Ultragenyx Pharmaceutical by 26.0% in the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 369 shares during the period. 97.67% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.